Needham Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $88 to $84.
August 06, 2024 | 10:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on CRISPR Therapeutics but lowers the price target from $88 to $84.
The maintained Buy rating is positive, but the lowered price target may temper investor enthusiasm. Overall, the impact is neutral as the positive rating balances the slightly reduced price target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100